News & Updates
Filter by Specialty:
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
03 Aug 2023Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
25 Jul 2023Rotavirus infection linked to gastroenteritis, neurological complications in children
Children with rotavirus infection are at risk of developing gastroenteritis with severe but self-limiting neurological manifestations, reveals a study.
Rotavirus infection linked to gastroenteritis, neurological complications in children
20 Jul 2023Phase III data support long-term efficacy of TAF against HBV
Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).